Legal Issues in Companion Diagnostics

On January 23rd, members of the Hogan Lovells Global Regulatory Health Care and FDA practice group will provide an in-depth presentation focused on Companion Diagnostics (CDx). The program...

HHS anti-kickback and Stark proposed rules: Impact on value-based care and longstanding regulatory hurdles

CMS and OIG proposed wide-ranging protections for value-based arrangements and provided guidance on a number of regulatory challenges under the AKS and Stark Law. On November 14, join us...

Boston Compliance Forum 2019

The Hogan Lovells Boston team along with regional and international colleagues is hosting an informative breakfast forum in Cambridge, MA on October 29, 2019. The event features two...

Proposed AKS rewrite on drug rebates: The impact and challenges ahead

The Trump Administration recently proposed what is arguably the most sweeping change to the regulatory safe harbors for the federal health care anti-kickback statute in decades. The...

Boston Compliance Forum

Join the Hogan Lovells Boston team along with regional and international colleagues for an informative breakfast forum in Cambridge, MA. The forum features two sessions that explore a range ...

Patient support programs: Understanding legal risks

Patient support programs – from nursing and reimbursement support services to copay support mechanisms – are industry-wide and increasingly important to patients facing an...

Pharmaceutical Enforcement Webinar Series

We invite you to attend a complimentary series of interdisciplinary webinars focused on the life sciences sector, hosted by Hogan Lovells lawyers in the FDA, Health, and White Collar...

Third Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies

Hogan Lovells is a sponsor of the Third Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies, which will provide expert advice on how to ...

Loading data